Abstract

Renal osteodystrophy, the term used to describe the skeletal complications of end-stage renal disease, is a multifactorial disorder of bone remodeling. The actions of some of the factors involved are well defined, and successful strategies have been designed to prevent them. For example, the identification of secondary hyperparathyroidism and 1α,25-dihydroxycholecalciferol (1α,25-dihydroxyvitamin D3) deficiency as major contributors to renal osteodystrophy has led to the development of treatment regimens that can maintain normal serum calcium and phosphate concentrations, reduce parathyroid hormone secretion, and correct a deficiency of 1α,25-dihydroxycholecalciferol. These improvements in treatment have resulted in decreases in the frequency and. . .

Original languageEnglish
Pages (from-to)166-175
Number of pages10
JournalNew England Journal of Medicine
Volume333
Issue number3
DOIs
StatePublished - Jul 20 1995

Fingerprint

Dive into the research topics of 'Renal osteodystrophy'. Together they form a unique fingerprint.

Cite this